Literature DB >> 21175595

Expansion of regulatory CD8+ CD25+ T cells after neonatal alloimmunization.

B Adams1, A Dubois, S Delbauve, I Debock, F Lhommé, M Goldman, V Flamand.   

Abstract

Transplantation tolerance induced by neonatal injection of semi-allogeneic spleen cells is associated with a pathological syndrome caused by T helper type 2 (Th2) differentiation of donor-specific CD4(+) T lymphocytes. We have shown previously that this Th2-biased response is inhibited by host CD8(+) T cells. Herein, we demonstrate that upon neonatal immunization with (A/J × BALB/c)F(1) spleen cells, BALB/c mice expand a population of CD8(+) T cells expressing both CD25 and forkhead box P3 (FoxP3) markers. In this setting, CD8(+) CD25(+) T cells predominantly produce interferon (IFN)-γ and interleukin (IL)-10 and are efficient in controlling IL-4, IL-5 and IL-13 production by donor-specific CD4(+) T cells in vitro. CD8(+) FoxP3(-) T cells are single producers of IFN-γ or IL-10, whereas CD8(+) FoxP3(+) T cells are double producers of IFN-γ and IL-10. We further demonstrate that IFN-γ and IL-10 are two major cytokines produced by CD8(+) T cells involved in the in vivo regulation of Th2-type pathology. In this setting, we conclude that neonatal alloimmunization induces the expansion of several regulatory CD8(+) T cells which may control Th2 activities via IFN-γ and IL-10.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21175595      PMCID: PMC3048619          DOI: 10.1111/j.1365-2249.2010.04299.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  CD8+ T lymphocytes regulating Th2 pathology escape neonatal tolerization.

Authors:  Brigitte Adams; Nathalie Nagy; Frédéric Paulart; Marie-Line Vanderhaeghen; Michel Goldman; Véronique Flamand
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity.

Authors:  Philippe Stock; Omid Akbari; Gerald Berry; Gordon J Freeman; Rosemarie H Dekruyff; Dale T Umetsu
Journal:  Nat Immunol       Date:  2004-09-26       Impact factor: 25.606

3.  Hypereosinophilic syndrome induced by neonatal immunization against MHC class II alloantigen: critical role of IL-4.

Authors:  Alain Le Moine; Véronique Flamand; Aurore de Lavareille; Frédéric Paulart; Sofia Buonocore; Marie-Line Vanderhaeghen; Nathalie Nagy; Claude Habran; Robert Kiss; Daniel Abramowicz; Michel Goldman
Journal:  Eur J Immunol       Date:  2002-01       Impact factor: 5.532

4.  CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation.

Authors:  Matthew J Thomas; Alistair Noble; Ela Sawicka; Philip W Askenase; David M Kemeny
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

5.  CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice.

Authors:  Q Gao; T M Rouse; K Kazmerzak; E H Field
Journal:  Transplantation       Date:  1999-12-27       Impact factor: 4.939

6.  Functional clonal deletion in immunological tolerance to major histocompatibility complex antigens.

Authors:  G J Nossal; B L Pike
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

7.  The role of interleukin-4 in the induction phase of allogeneic neonatal tolerance.

Authors:  Q Gao; N Chen; T M Rouse; E H Field
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

8.  Regulatory CD8+ T cells control neonatal tolerance to a Th2-mediated autoimmunity.

Authors:  Anne-Christine Field; Laure Caccavelli; Marie-Françoise Bloch; Blanche Bellon
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

9.  Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes.

Authors:  Lorenzo Cosmi; Francesco Liotta; Elena Lazzeri; Michela Francalanci; Roberta Angeli; Benedetta Mazzinghi; Veronica Santarlasci; Roberto Manetti; Vittorio Vanini; Paola Romagnani; Enrico Maggi; Sergio Romagnani; Francesco Annunziato
Journal:  Blood       Date:  2003-07-31       Impact factor: 22.113

10.  CD8(+) T cells regulate immune responses in a murine model of allergen-induced sensitization and airway inflammation.

Authors:  Philippe Stock; Tilmann Kallinich; Omid Akbari; David Quarcoo; Kerstin Gerhold; Ulrich Wahn; Dale T Umetsu; Eckard Hamelmann
Journal:  Eur J Immunol       Date:  2004-07       Impact factor: 5.532

View more
  5 in total

1.  Postnatal development of lung T lymphocytes in a porcine model.

Authors:  Angel J Balam-May; Carmen Ramírez-Estudillo; Gloria Lazo-Vázquez; Marco A Vega-López
Journal:  Lung       Date:  2014-07-17       Impact factor: 2.584

2.  Neonatal desensitization supports long-term survival and functional integration of human embryonic stem cell-derived mesenchymal stem cells in rat joint cartilage without immunosuppression.

Authors:  Shufang Zhang; Yang Zi Jiang; Wei Zhang; Longkun Chen; Tong Tong; Wanlu Liu; Qin Mu; Hua Liu; Junfeng Ji; Hong Wei Ouyang; Xiaohui Zou
Journal:  Stem Cells Dev       Date:  2012-08-14       Impact factor: 3.272

3.  Antibody-suppressor CD8+ T Cells Require CXCR5.

Authors:  Jason M Zimmerer; Bryce A Ringwald; Steven M Elzein; Christina L Avila; Robert T Warren; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2019-09       Impact factor: 4.939

4.  Pathophysiology of Alloimmunization.

Authors:  Rubiraida Molina-Aguilar; Soledad Gómez-Ruiz; Jorge Vela-Ojeda; Laura Arcelia Montiel-Cervantes; Elba Reyes-Maldonado
Journal:  Transfus Med Hemother       Date:  2019-08-06       Impact factor: 3.747

5.  Efficient isolation of human gingival stem cells in a new serum-free medium supplemented with platelet lysate and growth hormone for osteogenic differentiation enhancement.

Authors:  Ali Nassif; Benjamin Philippe Fournier; Ihsène Taihi; Caroline Pilon; José Cohen; Ariane Berdal; Bruno Gogly
Journal:  Stem Cell Res Ther       Date:  2022-03-25       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.